课题基金 / 基金详情

Regulation of smooth muscle-myosin phosphatase 1 kinase

Regulation of smooth muscle-myosin phosphatase 1 kinase
平滑肌肌球蛋白磷酸酶 1 激酶的调节
批准号:
7007662
负责人:
TIMOTHY A HAYSTEAD
金额:
$37.6万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-01-14 至 2008-12-31

项目摘要

项目成果

TIMOTHY A HAYSTEAD的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant: Smooth muscle plays an essential role in a wide variety of physiological processes, from the regulation of blood pressure by controlling vessel diameter in the periphery, to digestive processes by controlling mechanical movement of food though the gut, to reproductive functions by controlling penile erection and delivery of the fetus at birth, to regulation of lung capacity through regulation of airway diameter. A major factor governing the contractile state of all smooth muscles is the phosphorylation level of myosin light chain (LC20). In smooth muscle, steady state phosphorylation of LC20 is dictated by the opposing activities of myosin light chain kinase (MLCK) and myosin phosphatase (SMPP-1M). Inhibition of SMPP-1M activity through G protein coupled receptors acting through the small GTP binding protein RhoA has been shown to bring about calcium sensitization smooth muscle. Alterations in the sensitivity of various smooth muscles to calcium is hypothesized to be an underlying cause associated with many diseases associated with smooth muscle dysfunction such as hypertension, bronco spasm, sexual dysfunction, gastrointestinal disorders and glaucoma. Therefore signaling elements controlling myosin dephosphorylation state may represent attractive points of therapeutic intervention in a variety of human diseases associated with smooth muscle dysfunction. Recently our laboratory identified MYPT1 kinase (MYPT1 K) as a co-localizing SMPP-1M kinase that selectively phosphorylated the myosin targeting subunit (MYPT1) of the phosphatase and the inhibitor protein CPI17 to inhibit activity. Addition of constitutively active forms of MYPT1 K to permeabilized smooth muscles causes profound calcium sensitization through inhibition of SMPP-1M activity. In smooth muscle, MYPT1K is activated in response to a variety of calcium-sensitizing agonists and this activation can be blocked with the Rho kinase inhibitor Y-27632. These findings suggest MYPT1K mediates calcium-sensitizing signals from Rho kinase to SMPP-1M, however, the mechanisms by which MYPT1K is regulated in smooth muscle are unknown, since the protein kinase is not a direct substrate for Rho kinase in vitro. In this proposal we will employ a unique blend of muscle physiology, mass spectrometry, molecular biology, small interfering RNA's and small molecule chemistry to determine the molecular mechanisms by which Rho dependant signaling pathways bring about activation of MYPT1K in smooth muscle.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Acute Inhibition of TAK1 as a Means to Control COVID-19 Pulmonary Hyperinflammation
  • 批准号:
    10458667
  • 项目类别:
  • 资助金额:
    $28.47万
  • 财政年份:
    2021
  • 负责人:
    TIMOTHY A HAYSTEAD
  • 依托单位:
Preclinical Development of the TAK1 Inhibitor HS-276 for the Treatment of Rheumatoid Arthritis
  • 批准号:
    10259629
  • 项目类别:
  • 资助金额:
    $79.68万
  • 财政年份:
    2021
  • 负责人:
    TIMOTHY A HAYSTEAD
  • 依托单位:
Evaluating the Blood-Brain Barrier Bioavailability and in vivo Efficacy Potential of a Novel TAK1 Inhibitor Targeting Chronic Pain
  • 批准号:
    10151730
  • 项目类别:
  • 资助金额:
    $48.1万
  • 财政年份:
    2021
  • 负责人:
    TIMOTHY A HAYSTEAD
  • 依托单位:
Acute Inhibition of TAK1 as a Means to Control COVID-19 Pulmonary Hyperinflammation
  • 批准号:
    10158054
  • 项目类别:
  • 资助金额:
    $30.93万
  • 财政年份:
    2021
  • 负责人:
    TIMOTHY A HAYSTEAD
  • 依托单位: